ERBB2 and breast carcinoma: An aptamer-conjugated PROTAC designed to degrade HER2 protein has been shown to selectively target HER2-positive breast cancer cells, enhancing treatment precision and reducing off-target effects (He et al., 2021; Li et al., 2023).